Segmental System Proximal Femoral Component 38mm Offset 의 리콜

Department of Health, Therapeutic Goods Administration에 따르면, 해당 리콜 는 Australia 에서 Zimmer Biomet Pty Ltd 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    RC-2018-RN-00591-1
  • 사례 위험등급
    Class II
  • 사례 시작날짜
    2018-06-06
  • 사례 국가
  • 사례 출처
    DHTGA
  • 사례 출처 URL
  • 비고 / 경고
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • 데이터 추가 비고
  • 원인
    Zimmer biomet has received an overseas complaint regarding the segmental proximal femoral body 38mm offset alleging that the hole on the superior lateral aspect contained debris. an investigation determined that the debris was from the machining process that was not adequately removed during the subsequent cleaning process.To date, no adverse events have been reported as a result of this issue.
  • 조치
    Zimmer Bioment are advising Surgeons to maintain awareness of this issue, however, there are no specific patient monitoring instructions beyond the existing follow-up schedule for patients who have been implanted with these units.

Device

  • 모델명 / 제조번호(시리얼번호)
    Segmental System Proximal Femoral Component 38mm OffsetItem Number: 00585003038Multiple Lot NumbersARTG Number: 284862(Zimmer Biomet - Zimmer Segmental System, Proximal Femoral Component, 38mm offset - Uncoated femoral stem prosthesis, modular)
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source
    DHTGA